Investor Service Announcement no. 4/2011



To: NASDAQ OMX Copenhagen A/S
Hørsholm, Denmark, August 5, 2011






Veloxis Pharmaceuticals A/S to Present at the Cannacord Genuity Annual Growth
Conference



Veloxis Pharmaceuticals A/S (OMX: VELO), formerly LifeCycle Pharma A/S, today
announced that William J. Polvino, M.D., President and Chief Executive Officer,
will present at the Canaccord Genuity Annual Growth Conference at 4 p.m. EDT on
Tuesday, August 9, at the InterContinental Hotel in Boston. Dr. Polvino will
provide an overview of the company and its lead Phase 3 candidate, LCP-Tacro™,
to prevent organ transplant rejection. He will also discuss recently-announced
top-line results of the first Phase 3 trial in stable kidney transplant
patients.



For more information, please contact:



Veloxis Pharmaceuticals A/S
John Weinberg, M.D.
SVP, Commercial Operations & Investor Relations
Phone: +1 908 304 3389
Email: [email protected]

About Veloxis Pharmaceuticals


Based in Hørsholm, Denmark, with an office in New Jersey, Veloxis
Pharmaceuticals A/S, or Veloxis, is a specialty pharmaceutical company.
Clinical development is the core of Veloxis' efforts to develop a product
portfolio which includes the Company's lead product candidate, LCP‐Tacro™, for
immunosuppression, specifically organ transplantation, and products to combat
certain cardiovascular diseases. Veloxis adapts new technologies on a fast
commercial timetable. Veloxis' unique, patented delivery technology, MeltDose®,
can improve absorption and bioavailability ‐ at low‐scale up costs ‐ not only
for a broad spectrum of drugs already on the market but also for new chemical
entities. Veloxis has a lipid lowering product, Fenoglide®, currently on the
U.S. market and a diversified near and medium term pipeline with three clinical
stage product candidates and a number of projects in preclinical development.
Veloxis is listed on the NASDAQ OMX Copenhagen under the trading symbol OMX:
VELO.


For further information, please visit www.veloxis.com.

050811 Veloxis to present at Cannacord Genuity Annual Growth Conference.pdf